Journal Mobile Options
Table of Contents
Vol. 74, No. 1, 2005
Issue release date: December 2004
Psychother Psychosom 2005;74:36–42

Efficacy of Cognitive Behaviour Therapy in Generalized Anxiety Disorders

Results of a Controlled Clinical Trial (Berlin CBT-GAD Study)

Linden M. · Zubraegel D. · Baer T. · Franke U. · Schlattmann P.
aResearch Group Psychosomatic Rehabilitation, and bDepartment of Psychiatry and Psychotherapy, Biostatistical Division, Charité, University Hospital Benjamin Franklin, Berlin and cDepartment of Behavioural Medicine, BfA-Rehabilitation Centre Seehof, Teltow/Berlin, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Generalized anxiety disorders (GAD) are amongst the most prevalent mental disorders. Recent studies have suggested that cognitive behaviour therapy (CBT) is an effective treatment for GAD. A controlled clinical trial was done to evaluate the efficacy of CBT treatment in outpatients with pure GAD who were treated by a therapist working in routine care. Methods: Seventy-two outpatients, fulfilling GAD criteria according to DSM-IV, were included in the study. From this group, 36 patients (CBT-A) were randomly assigned to 25 sessions of CBT and the other 36 formed a contact control group (CCG). After the contact control period (CC period), these patients were also treated with CBT (CBT-B), allowing not only a parallel group comparison but also an A-B comparison. Therapists were licensed full-time psychologists who worked routinely in outpatient care and had a professional training in CBT. Treatment was done in accordance with a manual, and treatment conformity was controlled by several methods. Results: The reduction in the score on the Hamilton Anxiety Observer Rating Scale was 6.4% (1.5 points) in the CCG, 35.4% (9.5 points) in the CBT-A and 47.3% (10.3 points) in the CBT-B. In the self-rating Spielberger State-Trait Anxiety Inventory, a reduction of 2.7% was seen in CCG, 14.6% in CBT-A, and 11.6% in CBT-B. According to the Clinical Global Impression Rating, 65.6% of patients were still at least moderately ill at the end of the CC period, while this rate was 33.4% at the end of CBT-A, or 15.7% at the end of CBT-B. All these differences between treatment and control group are statistically highly significant. The clinical improvement remained stable over a follow-up period of 8 months. Conclusions: CBT is an effective method of treatment for GAD. Differences between control and treatment group are comparable to or larger than those reported in studies on antidepressant drugs.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, American Psychiatric Press, 1994.
  2. Borkovec TD, Newman MG: Worry and generalized anxiety disorder; in Salkovskis PM (ed): Clinical Formulation and Treatment. Oxford, Elsevier, 1999, pp 439–459.
  3. Dugas MJ: Generalized anxiety disorder publications: So where do we stand? J Anxiety Disord 2000;14:31–40.
  4. Linden M, Maier W, Achberger M, Herr R, Helmchen H, Benkert O: Psychische Erkrankungen und ihre Behandlung in Allgemeinarztpraxen in Deutschland. Ergebnisse aus einer Studie der Weltgesundheitsorganisation (WHO). Nervenarzt 1996;67:205–215.
  5. Carter RM, Wittchen HU, Pfister H, Kessler RC: One year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001;13:78–88.
  6. Wittchen HU, Hoyer J: Generalized anxiety disorder: Nature and course. J Clin Psychiatry 2001;62(suppl 11):15–21.

    External Resources

  7. Kessler RC, Keller MB, Wittchen HU: The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001;24:19–39.
  8. Brawman-Mintzer O, Lydiard RB: Generalized anxiety disorder: Issues in epidemiology. J Clin Psychiatry 1996;57(suppl 7):3–8.

    External Resources

  9. Brawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell MP, Ballenger JC: Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993;150:1216–1218.
  10. Dyck IR, Phillips KA, Warshaw MG, Dolan RT, Shea MT, Stout RL, Massion AO, Zlotnick C, Keller MB: Patterns of personality pathology in patients with generalized anxiety disorder, panic disorder with and without agoraphobia, and social phobia. J Personal Disord 2001;15:60–71.
  11. Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazadone, and diazepam. Arch Gen Psychiatry 1993;50:884–895.
  12. Roerig JL: Diagnosis and management of generalized anxiety disorder. J Am Pharmacol Assoc 1999;39:811–821.
  13. Ballenger JC: Current treatments of the anxiety disorders in adults. Biol Psychiatry 1999;46:1579–1594.
  14. Rocca P, Fonzo V, Scott M, Zanalda E, Ravizza L: Paroxetine efficay in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444–450.
  15. Davidson JRT, DuPont RL, Hedges D, Haskins JT: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528–535.
  16. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. A 6-month randomized controlled trial. J Am Med Assoc 2000;283:3082–3090.
  17. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK: Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350–357.
  18. Rickels K, Pollack MH, Sheehan DV, Haskins JT: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorders. Am J Psychiatry 2000;157:968–974.
  19. Hackett D: Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand Suppl 2000;406:30–35.
  20. Durham RC, Allan T: Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980. Br J Psychiatry 1993;163:19–26.
  21. Fisher PL, Durham RC: Recovery rates in generalized anxiety disorder following psychological therapy: An analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med 1999;29:1425–1434.
  22. Gould RA, Otto MW, Pollack MH, Yap L: Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. Behav Ther 1997;28:285–305.

    External Resources

  23. Ruhmland M, Margraf J: Effektivität psychologischer Therapien von generalisierter Angststörung und sozialer Phobie: Meta-Analysen auf Störungsebene. Verhaltenstherapie 2001;11:27–40.

    External Resources

  24. Borkovec TD, Ruscio AM: Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001;62:37–42.
  25. Butler G, Fennell M, Robson P, Gelder M: Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991;59:167–175.
  26. Barlow DH, Rapee RM, Brown TA: Behavioral treatment of generalized anxiety disorder. Behav Ther 1992;23:551–570.

    External Resources

  27. Borkovec TD, Costello E: Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993;61:611–619.
  28. Durham RC, Murphy T, Allan T, Richard K, Trevling LR, Fenton GW: Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. Br J Psychiatry 1994;165:315–323.
  29. Ladouceur R, Dugas MJ, Freeston MH, Leger E, Gagnon F, Thibodeau N: Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: Evaluation in a controlled clinical trial. J Consult Clin Psychol 2000;68:957–964.
  30. Öst LG, Breitholtz E: Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. Behav Res Ther 2000;38:777–790.
  31. Linden M (ed): Evaluative Psychotherapieforschung. Schwerpunktheft. Psychotherapie 2001;6:187–232.
  32. Linden M, Zubrägel D, Achberger M, Seidel K: Psychotherapiemanual zur kognitiv-verhaltenstherapeutischen Behandlung von generalisierten Angsterkrankungen bei Patienten ohne Response auf Pharmakotherapie. Free University of Berlin, 1995, unpubl manuscript.
  33. Zubrägel D, Linden, M: Generalisierte Angststörung; in Linden M, Hautzinger M (eds): Verhaltenstherapiemanual. Berlin, Springer, 2000.
  34. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The validity of the Mini-International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232–241.

    External Resources

  35. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22–33.

    External Resources

  36. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959,32:50–55.
  37. National Institute of Mental Health: Clinical Global Impression (German version); in Collegium Internationale Psychiatriae Scalarum (ed): Internationale Skalen für Psychiatrie. Göttingen, Beltz, 1996.
  38. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory (Form Y Self-Evaluation Questionnaire). Palo Alto, Consulting Psychologists Press, 1983.
  39. Linden M, Staats M, Bär T, Zubrägel D: Therapist compliance with manual guidelines in cognitive behavior therapy for generalized anxiety disorders as measured by the ‘Pivotal Topic Measure’. Results from the Berlin CBT-GAD-Study, submitted.
  40. Linden M, Zubrägel D: Multizentrische Psychotherapiestudien in Zusammenarbeit mit niedergelassenen Psychotherapeuten. Psychotherapie 2001;6:205–210.
  41. McCullagh P: Regression models for ordinal data. J R Stat Soc 1980;B42:109–142.
  42. Couvée JE, Bakker A, Zitman FG: The relevance of psychiatric and somatic comorbidity in depressed chronic benzodiazepine users. Psychother Psychosom 2002;71:263–268.
  43. Sharpe L, Ryan B, Allard S, Sensky T: Testing for the integrity of blinding in clinical trials: How valid are forced choice paradigms? Psychother Psychosom 2003;72:128–131.
  44. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115–127.
  45. Linden, M, Bär T, Zubrägel D, Ahrens B, Schlattmann P: Wirksamkeit der kognitiven Verhaltenstherapie bei generalisierten Angststörungen. Ergebnisse der Berliner KVT-GAD-Studie. Verhaltenstherapie 2002;12:173–181.

    External Resources

  46. Hautzinger M: Die Placebokontrollgruppe in der Psychotherapie. Psychotherapie 2001;6:199–204.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50